pulmonary diseases and Mediastinal diseases
Conditions
Interventions
Tubeless group:The patient underwent minimally invasive thoracic surgery with "tubeless" approach. During the operation, anesthesia was administered without endotracheal intubation. After the surgery,
Control group:The patient underwent conventional minimally invasive thoracic surgery. During the operation, general anesthesia with tracheal intubation was adopted. After the operation, a closed thora
Sponsors
The Affliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Intended to undergo minimally invasive thoracic surgery; 2. Age 18-20 years old, gender unrestricted; 3. American Society of Anesthesiologists (ASA) score of I-III; 4. Body Mass Index (BMI) = 1.5 x 109/L, platelets >= 100 x 109/L, hemoglobin >= 9 g/dL; • Liver function: Total bilirubin = 45 mL/min (Cockcroft-Gault formula); • Coagulation function: International Normalized Ratio (INR) or prothrombin time (PT) <= 1.5 times the upper limit of normal (ULN); 7. Able to understand and cooperate with the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patient-related factors: a. Patients who refuse surgery and/or the anesthesia plan; b. Patients with any severe or uncontrollable systemic diseases, such as: 1) Major and symptomatic severe arrhythmias, conduction abnormalities or morphological abnormalities on resting electrocardiogram that are difficult to control, such as second-degree or higher atrioventricular block, ventricular arrhythmias or atrial fibrillation; 2) Unstable angina pectoris, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) classification > grade 2; 3) Any arterial thrombosis, embolism or ischemia within 6 months before enrollment in the treatment, such as myocardial infarction, cerebrovascular accident or transient ischemic attack, etc.; 4) History of non-infectious pneumonia requiring glucocorticoid treatment within 1 year before the first administration, or current clinical active interstitial lung disease; 5) Active pulmonary tuberculosis; 6) Active or uncontrolled infection requiring systemic treatment; 7) Active diverticulitis, abdominal abscess, gastrointestinal obstruction; 8) Liver diseases such as liver cirrhosis, decompensated liver disease, acute or chronic active hepatitis; 9) Urine routine test showing urine protein >++, and confirmed 24-hour urine protein quantification > 1.0 g; 10) Patients with mental disorders and inability to cooperate with treatment; c. Relative contraindications: upper airway secretions or persistent cough; d. History of ipsilateral surgery and other conditions that may cause extensive pleural adhesions; e. Diaphragmatic nerve palsy on the non-surgical side; f. History or evidence of disease, treatment or abnormal laboratory test values that may interfere with the trial results or prevent the subject from fully participating in the study, or other situations deemed unsuitable for inclusion by the investigator. The investigator deems there are other potential risks that make the subject unsuitable for participation in this study. 2. Surgery-related factors: a. Extensive pleural adhesions; b. Previous ipsilateral lung surgery history; c. Preoperative pleural effusion; emphysematous lung, residual bullae.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pulmonary complications, PPCS;quality of recovery-15 scale (QoR-15); | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative ambulation time;postoperative length of stay;PO2, PCO2;Visual Analogue Scale (VAS) score;conversion rate;the percentage of neutrophilic granulocyte,CRP,IL-6,TNF,IFN;Nausea;Vomiting;Voice hoarseness;Sore throat; | — |
Countries
China
Contacts
Public ContactJiao Wenjie
The Affliated Hospital of Qingdao University
Outcome results
None listed